Nasdaq7d
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
Please note that Kisqali is already approved for the treatment of metastatic breast cancer (MBC) in several countries. The EC approval followed the recent FDA approval of Kisqali for EBC patients ...
Medscape23d
FDA Approvals
News, November 24, 2009 FDA Expands Use of Maraviroc to Include ... Pediatric Use of H1N1 Flu Vaccine CSL Limited has received approval for an expanded indication for its 2009 H1N1 influenza ...
Pharmabiz7d
Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
This news follows the recent US Food and Drug Administration (FDA) approval of Kisqali for EBC patients and recommendation as a Category 1 preferred breast cancer adjuvant treatment by the National ...
EuropaWire8d
Novartis Gains EU Approval for Kisqali® to Broaden Early Breast Cancer Treatment Options
Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an ...
Morningstar21d
FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above
"This FDA approval allows medical professionals (not just headache specialists) to offer the REN device so even more patients have access to an effective treatment option that is safe and not ...
pharmaphorum1d
FDA expands approval of Eli Lilly and Boehringer’s Tradjenta, for use with insulin
Following the first approval of generic versions of type 2 diabetes drug, Actos, the FDA has also approved updated prescribing information for Tradjenta tablets, for add-on therapy to insulin ...
Nasdaq8d
Novartis Kisqali Receives EU Approval For HR+/HER2- Early Breast Cancer At High Recurrence Risk
(RTTNews) - Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone ...